Marketing expansion, cost management lift Neimeth operating profit by 120%
Neimeth International Pharmaceuticals Plc experienced a 120% surge in operating profit for the first nine months of 2025, driven by sales/marketing expansion and cost containment. Revenue increased by 62% to N5.01 billion, and gross profit rose by 71%. While marketing and administrative costs were managed effectively, a significant 198% increase in finance costs impacted net profit, which still grew by 9% to N339.8 million. The company's total assets and liabilities increased, resulting in a 21% improvement in net assets. Strong cash flow from operations was offset by financing costs. Earnings Per Share rose to 7.95 kobo, leading to a rebound in the company's share price.
Sentiment: Positive (
0.80
)
Bias: Neutral
Fact-Checked Information
Source:
Google Fact Check Tools
Reliability:
Unknown
Notes:
No fact-checks found for this content
Verified on Nov 06, 2025